AAV vector for gene therapy

  • US 7,629,322 B2
  • Filed: 06/09/2004
  • Issued: 12/08/2009
  • Est. Priority Date: 06/11/2003
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method of gene therapy in a heart muscle tissue of a patient, comprising delivering to the heart muscle tissue of a patient an AAV-2 vector or an AAV-2 particle having a capsid encoded by the AAV-2 vector, wherein the AAV-2 vector comprises mutations R484E and R585E according to the numbering based upon VP1 protein, which are in a heparin binding motif of a capsid protein and cause a reduced or eliminated heparin binding function, and wherein said mutations are located on different subunits of the capsid protein.

View all claims

    Thank you for your feedback